SNDX Q1 2025 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$19M95.6% margin

Operating Income

-$84M-417.9% margin

Net Income

-$85M-423.3% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

+161.0%

Cash Flow

Operating Cash Flow

-$95M

Free Cash Flow

-$95M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$641M

Total Liabilities

$426M

Stockholders' Equity

$215M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$19M	$0	—
Operating Income	-$84M	-$80M	-5.3%
Net Income	-$85M	-$72M	-17.2%